Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · IEX Real-Time Price · USD
0.733
-0.377 (-33.96%)
May 8, 2024, 3:11 PM EDT - Market open
Seres Therapeutics Revenue
In the year 2023, Seres Therapeutics had annual revenue of $126.33M with 1,672.24% growth. Revenue in the quarter ending December 31, 2023 was $64.00K, a -93.44% decrease year-over-year.
Revenue (ttm)
$126.33M
Revenue Growth
+1,672.24%
P/S Ratio
0.90
Revenue / Employee
$542,167
Employees
233
Market Cap
112.58M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 126.33M | 119.20M | 1,672.24% |
Dec 31, 2022 | 7.13M | -137.80M | -95.08% |
Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
Dec 31, 2016 | 21.77M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accuray | 447.48M |
908 Devices | 50.73M |
Stereotaxis | 26.77M |
Inventiva | 25.74M |
MediWound | 18.69M |
Profound Medical | 5.41M |
Orchestra BioMed Holdings | 2.76M |
MCRB News
- 8 hours ago - Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Business Wire
- 1 day ago - Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 days ago - Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024 - Business Wire
- 4 weeks ago - Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT - Business Wire
- 5 weeks ago - VKTX, JANX and these biotech stocks are surging in 2024 - Invezz
- 2 months ago - Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates - Business Wire
- 2 months ago - Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024 - Business Wire
- 2 months ago - Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference - Business Wire